# AiLDS: AI Liver Disease Diagnosis System

This repository hosts a multi-stage diagnostic framework dedicated to evaluating the progression of **Liver Fibrosis** and predicting the probability of critical complications (Ascites) and mortality. The system relies on an ensemble of **XGBoost** training models, with its core logic distributed across three specialized files: `hepatitis_stage.pkl`, `hepatitis_complications.pkl`, and `hepatitis_status.pkl`. The model analyzes clinical input values based on "weights" acquired during the training phase, allowing for a precise determination of the risk level associated with each biomarker.

---

### Dataset Overview

| Name | Database Location | Function |
| --- | --- | --- |
| **hepatitis_stage.pkl** | `models/` | Trained model to classify histological damage (Stage 1-4). |
| **hepatitis_complications.pkl** | `models/` | Trained model to estimate the risk of Ascites. |
| **hepatitis_status.pkl** | `models/` | Trained model to calculate survival/mortality probability. |
| **train_hepatitis_models.py** | `code/` | Source code responsible for building and training the 3 models. |
| **test_hepatitis_models.py** | `code/` | Inference script for diagnosing the 7 cases (see details above). |
| **Hepatitis.csv** | `data/processed` | The processed clinical dataset derived from Mayo Clinic records. |
| **XGBoost.md** | `docs/` | Technical documentation explaining the mechanism of the XGBoost algorithm. |

---

### Training Phase

The system's efficiency depends on a data split of **80% for training** and **20% for testing**, ensuring the model learns robust patterns without memorizing the data.

> **Technical Note:** This split is considered the "Golden Standard" for medical datasets. It prevents the model from "hallucinating" or suffering from Overfitting, ensuring that high-risk stages (Stage 4) are identified based on generalized pathological patterns rather than specific patient identifiers.

---
## Data Pipeline & Feature Engineering

### 1. Data Source (Raw Data)

The primary dataset is sourced from the **Cirrhosis Prediction Dataset** hosted on Kaggle (provided by *fedesoriano*), which originates from the renowned **Mayo Clinic** study on primary biliary cirrhosis (PBC).

* **Original Source:** [Kaggle: Cirrhosis Prediction Dataset](https://www.kaggle.com/datasets/fedesoriano/cirrhosis-prediction-dataset)
* **Raw File Path:** `data/raw/cirrhosis.csv`
* **Description:** Contains historical clinical data collected between 1974 and 1984.

### 2. Feature Engineering Logic

To prepare the raw data for the **XGBoost** model, a rigorous **Data Engineering** phase was executed. The original file (`cirrhosis.csv`) was transformed into the processed training file (`Hepatitis.csv`) located in `data/processed`, resulting in a refined dataset of **419 patient records**.

The following transformations were applied:

#### **A. Target Variable Transformation (Status)**

The goal was to predict specific mortality risk. The original multi-class status was mapped to a binary format:

 **Original Values:**
* `C` (Censored) & `CL` (Censored due to Liver Transplant)  Considered **Stable**.
* `D` (Death)  Considered **Critical Event**.


* **Engineering Logic:**
```python
Status = { 'C': 0, 'CL': 0, 'D': 1 }  # 0: Alive/Stable, 1: Deceased

```



#### **B. Clinical Feature Encoding**

Categorical text values were converted into numerical formats to ensure mathematical compatibility with the model:

| Feature | Transformation Logic | Rationale |
| --- | --- | --- |
| **Age** | `Days / 365.25` | Converted from raw days to **Years** for clinical interpretability. |
| **Sex** | `M`  `1`, `F`  `0` | Binary encoding. |
| **Ascites** | `Y`  `1`, `N`  `0` | Presence vs. Absence. |
| **Hepatomegaly** | `Y`  `1`, `N`  `0` | Liver enlargement indicator. |
| **Spiders** | `Y`  `1`, `N`  `0` | Spider angiomas indicator. |

#### **C. Ordinal Severity Scaling (Edema)**

Unlike binary features, Edema has graduated severity levels. We applied **Ordinal Encoding** to reflect the increasing risk:

* **`N` (No Edema):** Mapped to **0.0**
* **`S` (Slight Edema):** Mapped to **0.5** (Edema resolvable with diuretics)
* **`Y` (Severe Edema):** Mapped to **1.0** (Edema resistant to diuretics)
---
_____________________________________
Ø¥Ù„ÙŠÙƒ ØªÙ†Ø³ÙŠÙ‚ Ø§Ø­ØªØ±Ø§ÙÙŠ ÙˆÙ…Ù†Ø¸Ù… Ù„Ù„Ù‚Ø³Ù…ÙŠÙ† Ø¨Ø­ÙŠØ« ÙŠÙƒÙ…Ù„ ÙƒÙ„ Ù…Ù†Ù‡Ù…Ø§ Ø§Ù„Ø¢Ø®Ø± Ø¯ÙˆÙ† ØªÙƒØ±Ø§Ø± Ù„Ù„Ù…Ø¹Ù„ÙˆÙ…Ø§ØªØŒ Ù…Ù…Ø§ ÙŠØ¬Ø¹Ù„ "Ø§Ù„Ù…Ù†Ø·Ù‚ Ø§Ù„Ø¨Ø±Ù…Ø¬ÙŠ" (Logic) Ø§Ù„Ø®Ø§Øµ Ø¨Ù…Ø´Ø±ÙˆØ¹Ùƒ ÙˆØ§Ø¶Ø­Ø§Ù‹ Ø¬Ø¯Ø§Ù‹ Ù„Ø£ÙŠ Ø´Ø®Øµ ÙŠÙ‚Ø±Ø£Ù‡ Ø¹Ù„Ù‰ GitHub:

---

# AiLDS: AI Liver Disease Diagnosis System

This repository hosts a multi-stage diagnostic framework dedicated to evaluating the progression of **Liver Fibrosis** and predicting the probability of critical complications and mortality. The system leverages an ensemble of **XGBoost** training models to transform complex clinical biomarkers into actionable diagnostic insights. By analyzing specific "feature weights" acquired during the training phase, AiLDS provides a precise determination of the risk levels associated with each patient's profile.

---

## Model Architecture & Integration

The predictive logic of the **AiLDS** is divided into three integrated diagnostic layers. Each layer acts as an independent specialized component, utilizing specific clinical features derived from the processed dataset to provide a comprehensive health assessment.

### 1. Model Breakdown & Feature Selection

| Model File | Input Features (Columns) | Target Output | Clinical Significance |
| --- | --- | --- | --- |
| **`hepatitis_stage.pkl`** | Core Blood Tests (Bilirubin, Albumin, SGOT, etc.) | Discrete Class: **1, 2, 3, 4** | Determines the level of histological liver scarring (Fibrosis). |
| **`hepatitis_complications.pkl`** | Blood Tests & Physical Signs (excluding 'Ascites') | Probability: **0.0 to 1.0** | Estimates the immediate risk of fluid accumulation (Ascites). |
| **`hepatitis_status.pkl`** | Blood Tests + **Predicted Stage** (from Model 1) | Probability: **0.0 to 1.0** | Calculates the ultimate mortality risk (Survival vs. Death). |

---

### 2. Understanding the `.pkl` Output

When interacting with these serialized models programmatically, the outputs are processed based on the task type:

* **Classification Output (Stage Model):** Returns a discrete numerical class representing the fibrosis stage.
> **Example:** An output of `3` corresponds to **Stage 4 (Cirrhosis)** in the clinical mapping.


* **Probability Output (Complications & Status Models):** We utilize the `predict_proba` function to retrieve a continuous value representing clinical confidence.
> **Example:** A result of `0.92` indicates a **92% probability** of a critical event or complication.



---

### 3. System Workflow & Double Verification Logic

AiLDS is engineered as a **Clinical Decision Support Tool**. To ensure the highest level of safety, the system follows a strict execution sequence and a custom verification protocol.

#### **A. Sequence of Execution**

The system logic is hierarchical. The predicted output of the **Stage Model** is critical because it serves as a high-weight feature for the final **Status Model**.

1. **Input Labs**  **Stage Prediction**.
2. **Input Labs + Predicted Stage**  **Mortality Risk Calculation**.

#### **B. The Double Verification Protocol (High-Risk Stages)**

Because the transition between Stage 3 (Advanced Fibrosis) and Stage 4 (Cirrhosis) is clinically critical, the system implements a **Double Verification Logic**.

* **Trigger:** If the Stage Model predicts a high-risk result (**Stage 3 or 4**), the system automatically re-runs the inference engine.
* **Requirement:** The model must return the **exact same result twice in a row**.
* **Safety Net:** If the two consecutive results are not identical, the system flags a "Verification Mismatch," preventing a potentially false high-risk diagnosis from being presented to the user.

---

### 4. Clinical Interpretation

The system categorizes results based on a probability threshold to assist in rapid triage:

* **ðŸŸ¢ Green Flag (Stable):** If the Mortality Probability is **< 50%**, the case is classified as stable with a recommendation for routine clinical monitoring.
* **ðŸ”´ Red Flag (Critical):** If the Mortality Probability is **> 50%**, the case is flagged as critical, requiring immediate medical intervention and further diagnostic confirmation.

---

### 5. Mathematical Validation

To complement the AI's predictive power, the system integrates established clinical scoring systems to provide a "ground truth" reference:

* **APRI Score (AST to Platelet Ratio Index):** Assesses the likelihood of significant fibrosis.


* **ALBI Score (Albumin-Bilirubin Grade):** Evaluates liver functional reserve.



---

Would you like me to prepare a professional `requirements.txt` file listing the specific versions of `xgboost`, `scikit-learn`, and `pandas` required to run these models on your system?
---

### 2- Model Input Requirements

To ensure result accuracy, data must be entered in the strict mathematical order used during the inference phase:
`['Bilirubin', 'Cholesterol', 'Albumin', 'Copper', 'Alk_Phos', 'SGOT', 'Tryglicerides', 'Platelets', 'Prothrombin', 'Age', 'Sex', 'Ascites', 'Hepatomegaly', 'Spiders', 'Edema']`

*Note: The `Status` model appends the predicted `Stage` to this list automatically.*

---

### Optimized Model Configuration

The following parameters were identified as the **"Gold Standard"** for this specific dataset to achieve maximum stability across the three models:

```python
# The optimized XGBoost configuration for Medical Diagnosis
model = xgb.XGBClassifier(
    n_estimators=100,      # Balanced number of trees to prevent complexity
    learning_rate=0.1,     # Optimal step size for stable convergence
    max_depth=3,           # Strategic depth to ensure high generalization
    subsample=0.8,         # Trains on 80% of data per tree to boost robustness
    eval_metric='logloss'  # Standard evaluation metric for binary classification
)

```

> **Scientific Insight:** In medical diagnostics, a `max_depth` of **3** is crucial. It forces the model to make decisions based on the most dominant biomarkers (like Bilirubin and Prothrombin) rather than creating complex, unexplainable branches that might fit noise in the data.

---

### 4. Virtual Clinic Test Results

To demonstrate the practical application of the model, a **"Virtual Clinic"** simulation was conducted using 7 real-world scenarios. This phase validates the model's ability to distinguish between "Structural Damage" (Stage) and "Functional Failure" (Status).

### Virtual Case Analysis Table

| Clinical Case | Brief Description | AI Stage | Survival Risk | Clinical Interpretation |
| --- | --- | --- | --- | --- |
| **1. The Healthy Reference** | Normal labs, no symptoms. | **Stage 1** | **1.4%** | Baseline reference for a low-risk profile. |
| **2. Acute Inflammation** | High Bilirubin (3.2), Stage 2. | **Stage 2** | **97.2%** | **Critical:** High mortality despite moderate fibrosis stage. |
| **3. Early Fibrosis** | Moderate APRI score. | **Stage 3** | **2.7%** | Disease is progressing but functionally stable. |
| **4. Compensated Cirrhosis** | Stage 4, but normal Albumin. | **Stage 4** | **0.6%** | **Key Result:** Successful clinical compensation (Type CL). |
| **5. Decompensated Failure** | Stage 4 + Ascites + Low Albumin. | **Stage 4** | **99.9%** | End-stage liver failure; immediate intervention required. |
| **6. Active Injury** | Stage 4 with high Enzymes (SGOT). | **Stage 4** | **92.5%** | High risk due to ongoing active inflammation. |
| **7. The Geriatric Case** | Age 70, Coagulation issues. | **Stage 4** | **98.9%** | Demonstrates the compounded risk of Age + Fibrosis. |

---

### Clinical Insights

Based on the Virtual Clinic outputs, critical technical observations regarding the AiLDS logic were derived:

#### **A. The "Compensated" Paradox (Case 4)**

The model successfully identified a patient with **Stage 4 Cirrhosis** yet assigned a very low mortality risk (**0.6%**). This reflects the clinical reality of "Compensated Cirrhosis," where the liver is scarred but still functional. This aligns with the "CL" (Censored/Transplant) data logic, proving the model is not blindly equating Stage 4 with Death.

#### **B. The Lethality of Bilirubin (Case 2)**

The model assigned a **97% risk** to a Stage 2 patient due to elevated Bilirubin (3.2). This confirms that **XGBoost** has correctly prioritized "Functional Markers" over "Structural Stage" when predicting immediate mortality.

#### **C. Multi-Factor Integration**

In Case 5, the convergence of **Ascites**, **Low Albumin**, and **High Copper** pushed the risk to **99.9%**, demonstrating the model's ability to handle complex, multi-variable failure cascading.
